Valentina Asamaigor
Psychiatric/Mental Health · Norcross, GANPI 1598347106
Payments from drug & device makers
Across 30 payments — averaging $70.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$521
- Johnson & Johnson$463
- Axsome Therapeutics, Inc.$227
- Alkermes, Inc.$217
- Neurocrine Biosciences, Inc.$160
- Grifols USA, LLC$136
- plus $377 from 6 others
What the payments were for
- Food & beverage$2,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $521 |
| Johnson & Johnson | 4 | $463 |
| Axsome Therapeutics, Inc. | 3 | $227 |
| Alkermes, Inc. | 2 | $217 |
| Neurocrine Biosciences, Inc. | 2 | $160 |
| Grifols USA, LLC | 1 | $136 |
| Corium, LLC | 2 | $135 |
| Supernus Pharmaceuticals, Inc. | 1 | $120 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| AbbVie | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,101 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 114 | $759 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $674 |
| Trazodone Hcl | 72 | $470 |
| Bupropion XlBupropion Hcl | 47 | $430 |
| Escitalopram Oxalate | 66 | $343 |
| Propranolol Hcl | 35 | $297 |
| Gabapentin | 55 | $259 |
| Hydroxyzine Hcl | 15 | $256 |
| Fluvoxamine Maleate | 16 | $250 |
| Hydroxyzine Pamoate | 28 | $232 |
| Buspirone Hcl | 26 | $222 |
| Clonazepam | 45 | $209 |
| Duloxetine Hcl | 15 | $161 |
| Alprazolam | 55 | $137 |
| Amitriptyline Hcl | 13 | $135 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Norcross
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.